Stockscreener 앱 받기
0.2252
5.66%
-0.0135
시간 외 거래:
.22
-0.0052
-2.31%
전일 마감가:
$0.2387
열려 있는:
$0.2387
하루 거래량:
3.20M
Relative Volume:
1.04
시가총액:
$14.09M
수익:
$895.50K
순이익/손실:
$-26.30M
주가수익비율:
-0.1179
EPS:
-1.91
순현금흐름:
$-23.84M
1주 성능:
+4.74%
1개월 성능:
-25.70%
6개월 성능:
-66.88%
1년 성능:
-81.39%
1일 변동 폭
$0.214
$0.2387
1주일 범위
$0.214
$0.3597
52주 변동 폭
$0.1852
$1.79
Mainz Biomed N V Stock (MYNZ) Company Profile
MYNZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| MYNZ | 0.2252 | 14.09M | 895.50K | -26.30M | -23.84M | -1.91 |
| TMO | 501.29 | 192.46B | 42.37B | 6.14B | 7.78B | 15.26 |
| DHR | 230.06 | 166.23B | 23.74B | 3.89B | 4.98B | 7.93 |
| A | 126.92 | 36.47B | 6.50B | 1.41B | 1.42B | 3.82 |
| IQV | 191.04 | 34.67B | 15.32B | 1.41B | 1.96B | 5.95 |
| IDXX | 419.83 | 34.38B | 3.84B | 866.24M | 792.60M | 9.80 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-06-21 | 개시 | H.C. Wainwright | Buy |
Mainz Biomed N V 주식(MYNZ)의 최신 뉴스
Mainz Biomed Considers Reverse Stock Split for Nasdaq Compliance - TipRanks
MAINZ BIOMED NV- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Thermo Fisher Scientific and Mainz Biomed Partner to Advance Colorectal Cancer Screening Technology - Citybuzz
Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening - Nasdaq
Mainz Biomed N.V. and Thermo Fisher Scientific Inc. Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets - Marketscreener.com
Mainz Biomed Partners With Thermo Fisher To Advance Colorectal Cancer Screening - Contract Pharma
Mainz Biomed and Thermo Fisher Scientific Sign a - GlobeNewswire
Mainz Biomed Partners with Thermo Fisher for Next-Gen Cancer Screening Breakthrough | MYNZ Stock News - StockTitan
Is Now The Time To Buy Mainz Biomed N.V. (NASDAQ: MYNZ) Stock? - Stocks Register
Mainz Biomed’s half-yearly revenue increases 4% YoY - Medical Buyer
Mainz Biomed reports revenue growth and reduced losses By Investing.com - Investing.com South Africa
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Mainz Biomed N : MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Form 6 K - Marketscreener.com
Financial Metrics Unveiled: Mainz Biomed N.V. (MYNZ)’s Key Ratios in the Spotlight - The Dwinnex
Mainz Biomed N.V.: Navigating Market Fluctuations with a 5.69M Market Cap - The InvestChronicle
Stocks of Mainz Biomed N.V. (MYNZ) are poised to climb above their peers - SETE News
Evaluating MYNZ’s financial ratios for a profitable investment - US Post News
Investors’ Faith in Mainz Biomed N.V. (MYNZ) could reap rewards if they hold on for the long haul - US Post News
Mainz Biomed Secures Additional $1.5M Funding - Yahoo Finance
Mainz Biomed N.V. [MYNZ] Stock trading around $0.38 per share: What’s Next? - The DBT News
Mainz Biomed N : Material Definitive Agreement Form 6 K - Marketscreener.com
Views of Wall Street’s Leading Experts on Mainz Biomed N.V. - SETE News
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version - GlobeNewswire
Mainz Biomed N.V.: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Understanding MYNZ’s book value per share for better investment insights - US Post News
Market Watch: Mainz Biomed N.V. (MYNZ)’s Noteworthy Drop, Closing at 0.24 - The Dwinnex
Mainz Biomed Executes Convertible Note Agreement - TipRanks
Mainz Biomed plans FDA trial for cancer test in 2025 - Investing.com India
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 - GlobeNewswire
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials - The Bakersfield Californian
Taking on analysts’ expectations and winning: Mainz Biomed N.V. (MYNZ) - SETE News
Mainz Biomed N.V. (MYNZ) Stock: A Year of Decreases and Increases - The InvestChronicle
Technical analysis of Mainz Biomed N.V. (MYNZ) stock chart patterns - US Post News
Market Highlights: Mainz Biomed N.V. (MYNZ) Ends on a High Note at 0.25 - The Dwinnex
What is Mainz Biomed N.V. (MYNZ) Stock Return on Shareholders’ Capital? - SETE News
Is Mainz Biomed N.V. (MYNZ) a good investment opportunity? - US Post News
Market Recap: Mainz Biomed N.V. (MYNZ)’s Negative Momentum, Closing at 0.24 - The Dwinnex
Mainz Biomed (NASDAQ:MYNZ) Stock Quotes, Forecast and News Summary - Benzinga
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador - GlobeNewswire
Financial Fitness Check: Examining Mainz Biomed N.V. (MYNZ)’s Key Ratios - The Dwinnex
It makes sense and dollars to buy Mainz Biomed N.V. (MYNZ) stock - SETE News
Mainz Biomed N.V. (MYNZ) deserves deeper analysis - US Post News
MYNZ Stock on the Rise: A Promising Investment - The InvestChronicle
Mainz Biomed to unveil breakthrough early cancer detection study results at DDW 2024 - MSN
Quarterly Snapshot: Quick and Current Ratios for Mainz Biomed N.V. (MYNZ) - The Dwinnex
Mainz Biomed stock plunges to 52-week low of $0.3 amid market challenges - Investing.com
Behind Mainz Biomed N.V.’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
Taking the lead: Mainz Biomed N.V. (MYNZ) - SETE News
MYNZ’s valuation metrics: A comprehensive analysis - US Post News
Insider’s View: Deciphering Mainz Biomed N.V. (MYNZ)’s Financial Health Through Ratios - The Dwinnex
Mainz Biomed and Liquid Biosciences Collaborate on Innovative Pancreatic Cancer Detection Tool - Vancity Buzz
Mainz Biomed N V (MYNZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.04%
3.19%
자본화:
|
볼륨(24시간):